Literature DB >> 33787861

Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.

Mikaël Roussel1,2, Kieu-Suong Le3, Clémence Granier4,5,6, Francisco Llamas Gutierrez7, Etienne Foucher3, Simon Le Gallou1,2, Céline Pangault1,2, Luc Xerri3, Vincent Launay8, Thierry Lamy1, Eric Tartour4,5,6, Daniel Olive3, Thierry Fest1,2.   

Abstract

In diffuse large B-cell lymphoma (DLBCL), tumor-infiltrating T lymphocytes (TILs) are involved in therapeutic responses. However, tumor-specific TILs can be dysfunctional, with impaired effector functions. Various mechanisms are involved in this exhaustion, and the increased expression of programmed cell death receptor 1 (PD1) and TIM3 on dysfunctional cells suggests their involvement. However, conflicting data have been published regarding their expression or coexpression in DLBCL. We evaluated the presence and phenotype of CD4+ and CD8+ TILs in freshly collected tumor tissues in DLBCL and compared the results with those in follicular lymphoma, classical Hodgkin lymphoma, and nonmalignant reactive lymphadenopathy. We found that TILs expressing both PD1 and TIM3 were expanded in DLBCL, particularly in the activated B cell-like subgroup. Isolated PD1+TIM3+ TILs exhibited a transcriptomic signature related to T-cell exhaustion associated with a reduction in cytokine production, both compromising the antitumor immune response. However, these cells expressed high levels of cytotoxic molecules. In line with this, stimulated PD1+TIM3+ TILs from DLBCL patients exhibited reduced proliferation and impaired secretion of interferon-γ, but these functions were restored by the blockade of PD1 or TIM3. In summary, the PD1+TIM3+ TIL population is expanded and exhausted in DLBCL but can be reinvigorated with appropriate therapies.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33787861      PMCID: PMC8045516          DOI: 10.1182/bloodadvances.2020003080

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  56 in total

Review 1.  Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski; Leticia Corrales; Jason Williams; Brendan Horton; Ayelet Sivan; Stefani Spranger
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

2.  Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Authors:  Dohee Kwon; Sehui Kim; Pil-Jong Kim; Heounjeong Go; Soo Jeong Nam; Jin Ho Paik; Young A Kim; Tae Min Kim; Dae Seog Heo; Chul Woo Kim; Yoon Kyung Jeon
Journal:  Histopathology       Date:  2015-12-01       Impact factor: 5.087

3.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

Authors:  Shin Foong Ngiow; Bianca von Scheidt; Hisaya Akiba; Hideo Yagita; Michele W L Teng; Mark J Smyth
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

4.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

5.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

6.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

7.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

8.  Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.

Authors:  Christopher Ronald Funk; Christopher T Petersen; Neera Jagirdar; Sruthi Ravindranathan; David L Jaye; Christopher R Flowers; Amelia Langston; Edmund K Waller
Journal:  Int J Mol Sci       Date:  2018-12-19       Impact factor: 5.923

9.  Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.

Authors:  Chulin Sha; Sharon Barrans; Francesco Cucco; Michael A Bentley; Matthew A Care; Thomas Cummin; Hannah Kennedy; Joe S Thompson; Rahman Uddin; Lisa Worrillow; Rebecca Chalkley; Moniek van Hoppe; Sophia Ahmed; Tom Maishman; Josh Caddy; Anna Schuh; Christoph Mamot; Catherine Burton; Reuben Tooze; Andrew Davies; Ming-Qing Du; Peter W M Johnson; David R Westhead
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544

10.  Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours.

Authors:  J Justin Milner; Clara Toma; Bingfei Yu; Kai Zhang; Kyla Omilusik; Anthony T Phan; Dapeng Wang; Adam J Getzler; Toan Nguyen; Shane Crotty; Wei Wang; Matthew E Pipkin; Ananda W Goldrath
Journal:  Nature       Date:  2017-12-06       Impact factor: 49.962

View more
  3 in total

1.  Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signaling.

Authors:  Adam M Greenbaum; Jonathan R Fromm; Ajay K Gopal; A McGarry Houghton
Journal:  Blood Res       Date:  2022-05-13

Review 2.  Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.

Authors:  Inna Serganova; Sanjukta Chakraborty; Samuel Yamshon; Yusuke Isshiki; Ryan Bucktrout; Ari Melnick; Wendy Béguelin; Roberta Zappasodi
Journal:  Front Cell Dev Biol       Date:  2022-01-07

3.  Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.

Authors:  Pauline Weimer; Jasmin Wellbrock; Tabea Sturmheit; Leticia Oliveira-Ferrer; Yi Ding; Stephan Menzel; Marius Witt; Louisa Hell; Barbara Schmalfeldt; Carsten Bokemeyer; Walter Fiedler; Franziska Brauneck
Journal:  Cells       Date:  2022-03-11       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.